Literature DB >> 31725168

Clinical Stages of Occult Macular Dystrophy Based on Optical Coherence Tomographic Findings.

Natsuko Nakamura1,2, Kazushige Tsunoda1, Yoshinobu Mizuno3, Tomoaki Usui4, Tetsuhisa Hatase5, Shinji Ueno6, Kazuki Kuniyoshi7, Takaaki Hayashi8, Satoshi Katagiri8, Mineo Kondo9, Shuhei Kameya10, Kazutoshi Yoshitake11, Kaoru Fujinami1,12,13, Takeshi Iwata11, Yozo Miyake1,14.   

Abstract

Purpose: To determine the course of occult macular dystrophy (OMD, Miyake's disease) and to propose stages of OMD based on the optical coherence tomographic (OCT) findings.
Methods: Sixty-one patients from 33 families with OMD who carried one of the proven variants of the RP1L1 gene were studied at seven centers in Japan. Ophthalmological examinations including the best-corrected visual acuity (BVCA) and OCT were performed.
Results: The median age at the last visit was 50 years with a range of 10 to 88 years, and the median age at the symptom onset was 30 years with a range of 3 to 60 years. There were significant negative correlations between the duration of OMD and BCVA, the central retinal thickness (CRT) and the thickness between external limiting membrane and retinal pigment epithelium (ERT). The BCVA gradually decreased for 10 years after symptom onset and was stable thereafter. Kaplan-Meier survival curves of the BCVA and retinal thickness showed that all of the patients had retained a vision of 1.0 logMAR, and over 80% of the patients had retained 50% thickness of the normal CRT and ERT for at least 60 years after symptom onset. The stages of OMD based on the visual symptoms and OCT findings are proposed. Conclusions: The photoreceptors do not become completely atrophic even at the late stage, which may account for the good retinal pigment epithelium (RPE) structure and normal-appearing fundus. The proposed stages facilitate the investigation of the pathogenicity of OMD and provide information to determine the effectiveness of therapeutic procedures.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31725168     DOI: 10.1167/iovs.19-27486

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Progress of macular atrophy during 30 months' follow-up in a patient with spinocerebellar ataxia type1 (SCA1).

Authors:  Ayane Hirose; Satoshi Katagiri; Takaaki Hayashi; Tomokazu Matsuura; Norihiro Nagai; Kaoru Fujinami; Takeshi Iwata; Kazushige Tsunoda
Journal:  Doc Ophthalmol       Date:  2020-07-09       Impact factor: 2.379

2.  Rare occult macular dystrophy with a pathogenic variant in the RP1L1 gene in a patient of Swiss descent.

Authors:  Olga Zabek; Ioannis Lamprakis; Annekatrin Rickmann; Giacomo Calzetti; Bence György; Hendrik P N Scholl; Maria Della Volpe Waizel
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-10

3.  Visual Field Characteristics in East Asian Patients With Occult Macular Dystrophy (Miyake Disease): EAOMD Report No. 3.

Authors:  Seong Joon Ahn; Lizhu Yang; Kazushige Tsunoda; Mineo Kondo; Yu Fujinami-Yokokawa; Natsuko Nakamura; Takeshi Iwata; Min Seok Kim; Yongseok Mun; Jun Young Park; Kwangsic Joo; Kyu Hyung Park; Yozo Miyake; Ruifang Sui; Kaoru Fujinami; Se Joon Woo
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

4.  Multimodal imaging evaluation of occult macular dystrophy associated with a novel RP1L1 variant.

Authors:  Lorenzo Bianco; Alessandro Arrigo; Alessio Antropoli; Paola Carrera; Ivana Spiga; Maria Grazia Patricelli; Francesco Bandello; Maurizio Battaglia Parodi
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-21

5.  Detailed analyses of microstructure of photoreceptor layer at different severities of occult macular dystrophy by ultrahigh-resolution SD-OCT.

Authors:  Kazushige Tsunoda; Gen Hanazono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.